Casirivimab

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-CD20 treatment antibody cocktail approved Asymptomatic Case report Case series case sery Casirivimab cilgavimab conducted coronavirus coronavirus disease coronavirus disease (COVID-19) COVID-19 infection develop dose European Evidence evidence of FIVE humoral Imdevimab immunomodulatory Immunotherapy impair incidence Infection Initially monoclonal monoclonal antibody multiple sclerosis Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody offered omicron Omicron variant one patient pandemic Patient patients positive RT-PCR predominant prophylactic treatment Prophylaxis receptor reduced respiratory respiratory tract infection response retained Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic SARS-CoV-2-neutralizing antibodies SARS-CoV-2-neutralizing antibody SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe adverse event severe adverse events Sotrovimab specific antibodies sphingosine sphingosine-1-phosphate sphingosine-1-receptor modulators (S1PR) sustained Symptom T-cell T-cells the patient the SARS-CoV-2 Tixagevimab Treatment union upper respiratory tract upper respiratory tract infection vaccination vaccination response variant were recorded
[DOI] 10.3389/fimmu.2022.897748 PMC 바로가기 [Article Type] Case Reports